Blinatumomab

Revision as of 13:49, 3 February 2015 by Aparna Vuppala (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span><...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Blinatumomab
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Blinatumomab is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Blinatumomab FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Blinatumomab in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Blinatumomab in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Blinatumomab FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Blinatumomab in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Blinatumomab in pediatric patients.

Contraindications

There is limited information regarding Blinatumomab Contraindications in the drug label.

Warnings

There is limited information regarding Blinatumomab Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Blinatumomab Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Blinatumomab Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Blinatumomab Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Blinatumomab in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Blinatumomab in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Blinatumomab during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Blinatumomab in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Blinatumomab in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Blinatumomab in geriatric settings.

Gender

There is no FDA guidance on the use of Blinatumomab with respect to specific gender populations.

Race

There is no FDA guidance on the use of Blinatumomab with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Blinatumomab in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Blinatumomab in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Blinatumomab in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Blinatumomab in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Blinatumomab Administration in the drug label.

Monitoring

There is limited information regarding Blinatumomab Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Blinatumomab and IV administrations.

Overdosage

There is limited information regarding Blinatumomab overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Blinatumomab Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Blinatumomab Mechanism of Action in the drug label.

Structure

There is limited information regarding Blinatumomab Structure in the drug label.

Pharmacodynamics

There is limited information regarding Blinatumomab Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Blinatumomab Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Blinatumomab Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Blinatumomab Clinical Studies in the drug label.

How Supplied

There is limited information regarding Blinatumomab How Supplied in the drug label.

Storage

There is limited information regarding Blinatumomab Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Blinatumomab |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Blinatumomab |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Blinatumomab Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Blinatumomab interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Blinatumomab Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Blinatumomab Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.